155 related articles for article (PubMed ID: 12617677)
1. 2D conformationally sampled pharmacophore: a ligand-based pharmacophore to differentiate delta opioid agonists from antagonists.
Bernard D; Coop A; MacKerell AD
J Am Chem Soc; 2003 Mar; 125(10):3101-7. PubMed ID: 12617677
[TBL] [Abstract][Full Text] [Related]
2. A three-dimensional model of the delta-opioid pharmacophore: comparative molecular modeling of peptide and nonpeptide ligands.
Shenderovich MD; Liao S; Qian X; Hruby VJ
Biopolymers; 2000 Jun; 53(7):565-80. PubMed ID: 10766952
[TBL] [Abstract][Full Text] [Related]
3. Conformationally sampled pharmacophore for peptidic delta opioid ligands.
Bernard D; Coop A; MacKerell AD
J Med Chem; 2005 Dec; 48(24):7773-80. PubMed ID: 16302816
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2006 Jan; 49(1):256-62. PubMed ID: 16392810
[TBL] [Abstract][Full Text] [Related]
5. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
6. Complementarity of delta opioid ligand pharmacophore and receptor models.
Mosberg HI
Biopolymers; 1999; 51(6):426-39. PubMed ID: 10797231
[TBL] [Abstract][Full Text] [Related]
7. Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
Subramanian G; Paterlini MG; Larson DL; Portoghese PS; Ferguson DM
J Med Chem; 1998 Nov; 41(24):4777-89. PubMed ID: 9822548
[TBL] [Abstract][Full Text] [Related]
8. Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity.
Bernard D; Coop A; MacKerell AD
J Med Chem; 2007 Apr; 50(8):1799-809. PubMed ID: 17367120
[TBL] [Abstract][Full Text] [Related]
9. Conformational analysis and pharmacophore design for selected 1-(2-pyrimidinyl)piperazine derivatives with sedative-hypnotic activity.
Bronowska A; Leś A; Mazgajska M; Chilmończyk Z
Acta Pol Pharm; 2001; 58(2):79-86. PubMed ID: 11501794
[TBL] [Abstract][Full Text] [Related]
10. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
Axe FU; Bembenek SD; Szalma S
J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
[TBL] [Abstract][Full Text] [Related]
11. Parameterization and conformational sampling effects in pharmacophore multiplet searching.
Fox PC; Wolohan PR; Abrahamian E; Clark RD
J Chem Inf Model; 2008 Dec; 48(12):2326-34. PubMed ID: 19053520
[TBL] [Abstract][Full Text] [Related]
12. 3D-QSAR comparative molecular field analysis on delta opioid receptor agonist SNC80 and its analogs.
Peng Y; Keenan SM; Zhang Q; Welsh WJ
J Mol Graph Model; 2005 Sep; 24(1):25-33. PubMed ID: 15950508
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
Neumeyer JL; Zhang A; Xiong W; Gu XH; Hilbert JE; Knapp BI; Negus SS; Mello NK; Bidlack JM
J Med Chem; 2003 Nov; 46(24):5162-70. PubMed ID: 14613319
[TBL] [Abstract][Full Text] [Related]
14. A self-organizing algorithm for molecular alignment and pharmacophore development.
Bandyopadhyay D; Agrafiotis DK
J Comput Chem; 2008 Apr; 29(6):965-82. PubMed ID: 17999384
[TBL] [Abstract][Full Text] [Related]
15. Molecular modeling of sigma 1 receptor ligands: a model of binding conformational and electrostatic considerations.
Gund TM; Floyd J; Jung D
J Mol Graph Model; 2004 Jan; 22(3):221-30. PubMed ID: 14629980
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of Leu-Enkephalin analog with (4-Carboxamido)phenylalanine substituted for tyrosine: a molecular dynamics study.
Wang YC; Wu YC; Yeh CC; Hwang CC
Biopolymers; 2007 Jun; 86(3):231-9. PubMed ID: 17377963
[TBL] [Abstract][Full Text] [Related]
17. Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.
Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH
J Med Chem; 2004 Jul; 47(16):4066-71. PubMed ID: 15267245
[TBL] [Abstract][Full Text] [Related]
18. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of alphaS1-casomorphin using AM1 calculations and molecular dynamics simulations.
Wu YC; Lin JS; Hwang CC
J Phys Chem B; 2007 Jun; 111(25):7377-83. PubMed ID: 17530883
[TBL] [Abstract][Full Text] [Related]
20. Development of a quasi-dynamic pharmacophore model for anti-complement peptide analogues.
Mallik B; Morikis D
J Am Chem Soc; 2005 Aug; 127(31):10967-76. PubMed ID: 16076203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
